| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| MNKDMannKind Corporation | 1.73B | 5.64 | 58.02 | 43.5% | 9.32% | 1.89% | ||
| CORTCorcept Therapeutics Incorporated | 3.82B | 36.35 | 29.55 | 39.94% | 14.19% | 16.65% | 5.12% | 0.01 |
| GUTSFractyl Health, Inc. Common Stock | 308.28M | 2.01 | -1.24 | -22.5% | -40732.33% | -241.68% | 2.20 | |
| LXRXLexicon Pharmaceuticals, Inc. | 436.08M | 1.20 | -1.90 | 24.81% | -96.77% | -57.07% | 0.74 | |
| RZLTRezolute, Inc. | 229.96M | 2.48 | -2.53 | -52.45% | 0.01 | |||
| MISTMilestone Pharmaceuticals Inc. | 164.38M | 1.93 | -2.88 | -100% | -282.97% | 4.17 | ||
| ALTAltimmune, Inc. | 418.41M | 4.01 | -2.99 | -95.31% | -4195.75% | -45.21% | 0.01 | |
| BIOABioAge Labs, Inc. | 741.84M | 20.69 | -3.12 | -12.81% | -27.32% | 0.03 |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 |
| Revenue Growth % | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - |
| Gross Profit | 0 | 0 | 0 |
| Gross Margin % | - | - | - |
| Gross Profit Growth % | - | - | - |
| Operating Expenses | 11.36M | 7.42M | 22.79M |
| OpEx % of Revenue | - | - | - |
| Selling, General & Admin | 2.7M | 2.17M | 5.3M |
| SG&A % of Revenue | - | - | - |
| Research & Development | 7.17M | 4.48M | 17.36M |
| R&D % of Revenue | - | - | - |
| Other Operating Expenses | 1.49M | 762K | 117K |
| Operating Income | -11.36M | -7.42M | -22.79M |
| Operating Margin % | - | - | - |
| Operating Income Growth % | - | 0.35% | -2.07% |
| EBITDA | -11.25M | -6.65M | -22.77M |
| EBITDA Margin % | - | - | - |
| EBITDA Growth % | - | 0.41% | -2.42% |
| D&A (Non-Cash Add-back) | 110K | 0 | 16K |
| EBIT | -9.87M | -6.65M | -22.67M |
| Net Interest Income | 120K | 1.42M | 2.41M |
| Interest Income | 120K | 1.42M | 2.41M |
| Interest Expense | 0 | 0 | 0 |
| Other Income/Expense | -2.2M | 207K | 2.2M |
| Pretax Income | -13.56M | -7.21M | -20.59M |
| Pretax Margin % | - | - | - |
| Income Tax | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% |
| Net Income | -13.56M | -7.21M | -20.59M |
| Net Margin % | - | - | - |
| Net Income Growth % | - | 0.47% | -1.86% |
| Net Income (Continuing) | -13.56M | -7.21M | -20.59M |
| Discontinued Operations | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| EPS (Diluted) | -1.39 | -0.56 | -1.59 |
| EPS Growth % | - | 0.6% | -1.84% |
| EPS (Basic) | -1.39 | -0.56 | -1.59 |
| Diluted Shares Outstanding | 9.73M | 12.91M | 12.91M |
| Basic Shares Outstanding | 9.73M | 12.91M | 12.91M |
| Dividend Payout Ratio | - | - | - |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Total Current Assets | 16.49M | 10.37M | 74.14M |
| Cash & Short-Term Investments | 16.11M | 9.99M | 73.66M |
| Cash Only | 15.56M | 9.73M | 61.64M |
| Short-Term Investments | 546K | 254K | 12.02M |
| Accounts Receivable | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - |
| Inventory | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - |
| Other Current Assets | 70K | 127K | 160K |
| Total Non-Current Assets | 266K | 168K | 3.37M |
| Property, Plant & Equipment | 252K | 155K | 735K |
| Fixed Asset Turnover | - | - | - |
| Goodwill | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 |
| Other Non-Current Assets | 14K | 13K | 2.63M |
| Total Assets | 16.76M | 10.54M | 77.51M |
| Asset Turnover | - | - | - |
| Asset Growth % | - | -0.37% | 6.36% |
| Total Current Liabilities | 595K | 1.38M | 4.93M |
| Accounts Payable | 259K | 1.03M | 2.3M |
| Days Payables Outstanding | - | - | - |
| Short-Term Debt | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 |
| Other Current Liabilities | 53K | 45K | 896K |
| Current Ratio | 27.72x | 7.50x | 15.05x |
| Quick Ratio | 27.72x | 7.50x | 15.05x |
| Cash Conversion Cycle | - | - | - |
| Total Non-Current Liabilities | 44.09M | 43.96M | 127.22M |
| Long-Term Debt | 0 | 0 | 0 |
| Capital Lease Obligations | 162K | 50K | 441K |
| Deferred Tax Liabilities | 0 | 0 | 0 |
| Other Non-Current Liabilities | 43.92M | 43.91M | 126.78M |
| Total Liabilities | 44.68M | 45.34M | 132.15M |
| Total Debt | 262K | 162K | 779K |
| Net Debt | -15.3M | -9.57M | -60.86M |
| Debt / Equity | - | - | - |
| Debt / EBITDA | - | - | - |
| Net Debt / EBITDA | - | - | - |
| Interest Coverage | - | - | - |
| Total Equity | -27.92M | -34.8M | -54.64M |
| Equity Growth % | - | -0.25% | -0.57% |
| Book Value per Share | -2.87 | -2.70 | -4.23 |
| Total Shareholders' Equity | -27.92M | -34.8M | -54.64M |
| Common Stock | 0 | 0 | 0 |
| Retained Earnings | -30.53M | -37.74M | -58.33M |
| Treasury Stock | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Cash from Operations | -10.54M | -5.82M | -18.09M |
| Operating CF Margin % | - | - | - |
| Operating CF Growth % | - | 0.45% | -2.11% |
| Net Income | -13.56M | -7.21M | -20.59M |
| Depreciation & Amortization | 110K | 97K | 16K |
| Stock-Based Compensation | 412K | 313K | 439K |
| Deferred Taxes | 0 | 0 | 0 |
| Other Non-Cash Items | 3.81M | 1.05M | 473K |
| Working Capital Changes | -1.31M | -81K | 1.57M |
| Change in Receivables | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 |
| Change in Payables | 31K | 776K | 798K |
| Cash from Investing | -1M | 0 | -12M |
| Capital Expenditures | 0 | 0 | -109K |
| CapEx % of Revenue | - | - | - |
| Acquisitions | - | - | - |
| Investments | - | - | - |
| Other Investing | -1M | 0 | 0 |
| Cash from Financing | 225K | 0 | 81.99M |
| Debt Issued (Net) | - | - | - |
| Equity Issued (Net) | - | - | - |
| Dividends Paid | 0 | 0 | 0 |
| Share Repurchases | - | - | - |
| Other Financing | 1M | 0 | -3.34M |
| Net Change in Cash | - | - | - |
| Free Cash Flow | -10.54M | -5.82M | -18.2M |
| FCF Margin % | - | - | - |
| FCF Growth % | - | 0.45% | -2.12% |
| FCF per Share | -1.08 | -0.45 | -1.41 |
| FCF Conversion (FCF/Net Income) | 0.78x | 0.81x | 0.88x |
| Interest Paid | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| FCF Conversion | 0.78x | 0.81x | 0.88x |
Aardvark Therapeutics, Inc. Common Stock (AARD) grew revenue by 0.0% over the past year. Growth has been modest.
Aardvark Therapeutics, Inc. Common Stock (AARD) reported a net loss of $48.8M for fiscal year 2024.
Aardvark Therapeutics, Inc. Common Stock (AARD) had negative free cash flow of $47.6M in fiscal year 2024, likely due to heavy capital investments.